Shailendra Giri

This study identifies treatment-specific miRNA response signatures in RRMS patients following cladribine or ocrelizumab, revealing distinct molecular programs associated with each therapy.

This study identifies succinate accumulation in aged ovarian tumor microenvironments as a driver of Treg dysfunction, suggesting metabolic targeting as a strategy to restore antitumor immunity.

This study shows CPI-613 reduces tumor growth in chemoresistant ovarian tumors by inhibiting mitochondrial function and enhancing chemotherapy response.

This study uses untargeted metabolomics to identify altered serum metabolites distinguishing relapsing-remitting MS, progressive MS, and healthy subjects.

This study shows that loss of AMPK after traumatic brain injury in mice worsens inflammation and behavioral outcomes by increasing inflammasome activation and proinflammatory cytokines.

This study shows Nrf2 modulates CD4+ T-cell activation and expansion by altering glucose and glutamine metabolism, offering insights for improving immunotherapies.

This study shows that MaR1 treatment reduces inflammation, protects neurons, and improves metabolism in a mouse model of multiple sclerosis.

This study shows that pyruvate dehydrogenase (Pdh) activity is critical for oligodendrocyte maturation and remyelination by regulating mitochondrial respiration and Olig1 acetylation.

The paper identifies altered metabolic pathways in RRMS patients using metabolomics and shows that targeting glycolysis can reduce disease progression in a mouse model.